The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Subscribe To Our Newsletter & Stay Updated
